Regulatory Affairs
Addressing the 801-Day Lag: Irelandโs Drug Approval System Demands Urgent Structural Reform
The latest EFPIA Patients W.A.I.T. Indicator report reveals that Irish patients wait an average of 801 days to access newly approved medicines, prompting calls for an overhaul of the HSE and NCPE reimbursement processes and a dedicated mechanism for rare disease orphan drugs.

Industry
Beyond Google: Why B2B Pharma is Adopting 'Search Everywhere' and Generative Engine Optimization (GEO) in 2026
As professional buyers shift from search engines to AI assistants and LinkedIn for vendor research, B2B pharmaceutical and life science companies are pivoting from traditional keyword rankings to "Search Everywhere" and Generative Engine Optimization (GEO).

Industry
University of Galway to Lead New โฌ64.5m Research Ireland Rinn Medical Devices Centre
The University of Galway has been chosen to lead the new โฌ64.5 million Research Ireland Rinn Medical Devices Centre as part of a landmark โฌ460 million government investment in seven new national Rinn research centres.

Industry
Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026
Chanelle Pharma has confirmed the renewal of its long-standing partnership with the Galway Races Summer Festival for 2026, marking 41 consecutive years of sponsoring the prestigious Leading Trainer Award alongside the Best Turned Out Series.

Industry
The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape
Ireland's contract manufacturing exports-colloquially known as "phantom exports"-are surging once again, raising fresh questions about the decoupling of headline economic figures from the domestic life sciences economy.

Pharmaceutical
The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterfordโs FDA Audit
The FDA CBER warning letter issued to Genzyme Irelandโs Waterford site in June 2026 is a watershed moment for Irish biopharma. From 11x repeated filter tests to discarded checklists and unexplained deviation cancellations, we analyze the specific CGMP violations and detail what this compliance failure means for quality management across the sector.

Pharmaceutical
The Complete LinkedIn Brand-Building Playbook for Pharma and Life Sciences
LinkedIn is the most powerful platform for pharmaceutical and life sciences professionals to build authority and reach target customers. This complete guide covers company page setup, what to post, best times to publish, how to grow connections, and how to turn LinkedIn into a consistent pipeline.

Pharmaceutical
The Newsletter Advantage: How Pharma Companies Use Email to Reach the Right People Every Time
Newsletters are the most cost-effective marketing tool for pharmaceutical companies. Unlike social media, a newsletter lands directly in the inbox of every person who chose to hear from you. This step-by-step guide explains how to set one up, what to put in it, and how to reach target customers efficiently.

Biotechnology
The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition
In a deal announced on July 7, 2026, Woodberry Packaging - the Dublin-backed packaging group led by veteran entrepreneur Patrick Doran - has acquired Medica Packaging, the UK's largest independent pharmaceutical carton converter, and F.G. Curtis, a respected name in cosmetics and personal care packaging. The combined group now employs 650 people across the UK and Ireland with revenues exceeding โฌ120 million, marking a significant consolidation moment in the specialist packaging sector.

Regulatory Affairs
The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected
Jefferies has revised its debut-quarter US sales estimate for Eli Lilly's oral GLP-1 drug Foundayo (orforglipron) down to $71 million - well below the Wall Street consensus of $130 million and sharply below its own prior estimate of $85 million. With weekly prescriptions hovering around 20,000 and Novo Nordisk's oral Wegovy outpacing it on trajectory, the first oral non-peptide GLP-1 for obesity is generating a very different story than the hype suggested.

Regulatory Affairs
Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots
The UK government and the pharmaceutical industry have launched a series of pilot schemes designed to accelerate NHS patient access to innovative medicines - a direct consequence of the US-UK pharmaceutical trade arrangement that has already rewritten the terms of how Britain prices, approves, and funds new drugs. But with a BMJ analysis warning of ยฃ45 billion in diverted NHS resources and up to 229,000 excess deaths by 2036, the pilots are arriving in the middle of one of the most contested healthcare policy disputes in a generation.

MedTech
Cork MedTech Innovator NeuroBell Secures $5.5M to Accelerate Launch of AI Neonatal Seizure Monitor Luna
NeuroBell, a spin-out from University College UCC, has closed a $5.5 million (โฌ4.8 million) funding round led by Elkstone to secure US regulatory clearance and commercialize its AI-powered neonatal seizure detection device, Luna.
